Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980
Manchester, UK, September 17, 2024 Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United Kingdom Intellectual Property Office (“IPO”) has granted UK patent GB2616923, in support of MT1980, an anti-neuroinflammatory compound using novel brain-targeting technology. The patent, which is set to […]
Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development.
Manchester, UK, and Cambridge UK, 18 April 2024 Monument Therapeutics, a precision neuroscience company, today announced new funding of £1.5 million from a combination of equity investment and non-dilutive grant as part of the Innovate UK Future Economy Investor Partnership programme. The round was led by Cambridge Angels, one of the UK’s leading business angel […]
Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
Manchester, UK, January 4, 2024 – Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,862,337, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS). The […]
Our Head of Development, Sheryl Caswell is featured in the CCRA Yearbook discussing the impact of digital biomarkers on clinical research
Biomarkers have become increasingly important in the drug development process. But what is a biomarker and why are they useful to enable clinical trial design? Click here to download the PDF
Post-Covid-19 cognitive impairment: a new target for drug development?
Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne, and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. Click here to read the article online Alternatively, click here to download the PDF
Stratified neuroscience company Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation, at AD/PD conference
Monument Tx CSO to present positive data from first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, at AD/PD conference March 28th-April 1st 2023 Manchester, UK, March 27th, 2023: Monument Therapeutics, a stratified neuroscience company, today announced they will be presenting positive results from their lead clinical program at the AD/PD conference, March 28th–April […]
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives Monument Tx announce first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, shows drug can access the brain San Francisco, USA, January 8, 2023: Monument Therapeutics, a stratified neuroscience company, will this week […]
The rise of digital biomarkers in neuroscience drug development
Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J. Mark Treherne, Dr Jenny Barnett and Dr Paula Moran. Click here to download the article
Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference
Stratified medicine company Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive digital biomarker and drug MT1988 to treat […]
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation Monument Tx announce first-in-human study of MT1980, a novel treatment for neuroinflammation Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel […]
We are attending the BIO Conference: join us at two exciting sessions
We will be participating at the upcoming Biotechnology Innovation Organization conference taking place in San Diego, California, June 13-16. Members of our team will be speaking at two incredibly exciting sessions: Tackling Post-Covid Cognitive Impairment Wednesday, June 15th, 4:15pm – 5:15pm PDT https://www.bio.org/events/bio-international-convention/sessions/916081 Speaker: Dr Kiri Granger, Monument Tx, CSO Widespread evidence shows that cognitive problems are the […]
Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)
Proud that our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (#POCD). As the article notes, estimates suggest that the overall incidence of POCD in older patients can be as high as 50-80% at discharge, 20-50% at six weeks and 10-30% at six months post-surgery. New therapies are […]
Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!
We are very proud that our fantastic CSO Dr Kiri Granger has been listed as one of In Vivo‘s 2022 ‘Rising Leaders’! The third annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care. Included for 2022 are investors, CEOs of small and mid-sized […]
New Interview in Scrip
New interview in Scrip! Read more about our novel approach to CNS drug development and our focus on repurposing existing drugs with the aid of digital biomarkers. Read the interview here. For further information, contact: Jenny Barnett, CEO E: jbarnett@monumenttx.com Media: Richard Hayhurst/Janet Joy E: Richard@rhapr.eu or jan@rhapr.eu Tel: +44 7711 821527 Notes to Editors: […]
